DEFA14A: Castle Biosciences Addresses Stockholder Concerns on Executive Pay, Urges 'For' Vote on Say-on-Pay Proposal

Castle Biosciences issues a letter to stockholders highlighting changes made to executive compensation in response to stockholder feedback, urging a vote in favor of the Say-on-Pay proposal at the upcoming Annual Meeting.

Summary

• Castle Biosciences filed a supplemental proxy statement on May 10, 2024, to address stockholder concerns regarding executive compensation.
• The company is urging stockholders to vote 'FOR' Proposal 3, the advisory vote on named executive officer compensation (Say-on-Pay), at the Annual Meeting on May 23, 2024.
• Following the 2023 annual stockholder meeting, Castle Biosciences engaged with its largest institutional stockholders, representing 57% of outstanding common stock, to gather feedback on executive compensation.
• Key concerns raised by stockholders included short-term performance hurdles in long-term incentives, overlapping metrics in shortand long-term incentives, a desire for CEO pay to align with company performance and size, and the need for enhanced compensation disclosures and risk mitigation practices.
• In response to these concerns, the company moved to a 3-year performance period for performance-based equity grants, added new 3-year performance metrics (commercial pipeline testing goals and achieving positive EBITDA by the end of 2026) separate from short-term incentive metrics, and re-examined the peer group to better align with the company's revenue and market capitalization.
• The company also moved the annual equity grant to the first quarter to better align with the full year's performance, maintained 50% of the CEO's annual award as performance-based, expanded disclosure surrounding the CEO pay setting process, and formally adopted stock ownership guidelines and a clawback policy.
• The company grew revenue by 60% to $220 million in fiscal year 2023 and delivered 70,429 test reports, representing growth of 59% compared to 2022.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment by highlighting the company's responsiveness to stockholder concerns and its strong financial performance. The proactive engagement with stockholders and the implementation of changes to address their feedback are viewed favorably.

Positives

• Castle Biosciences actively engaged with stockholders to address concerns regarding executive compensation.
• The company implemented changes to its executive compensation practices in direct response to stockholder feedback.
• The company is providing enhanced compensation disclosures to improve transparency.
• The company adopted risk mitigation practices, including stock ownership guidelines and a clawback policy.
• The company achieved significant revenue growth of 60% in fiscal year 2023.
• The company achieved significant test report growth of 59% in fiscal year 2023.

Negatives

• Stockholders raised concerns about short-term performance hurdles in long-term incentives.
• Stockholders raised concerns about overlapping metrics in shortand long-term incentives.
• Stockholders expressed a desire for CEO pay to better align with company performance and size.
• Ten of the 15 largest institutional stockholders declined to meet with the company during the outreach program.

Risks

• Failure to address stockholder concerns regarding executive compensation could lead to negative votes on the Say-on-Pay proposal.
• The company's ability to achieve its financial and pipeline goals is subject to various risks and uncertainties.
• The company's compensation practices may not be fully aligned with stockholder expectations, despite the changes made.

Future Outlook

The company aims to drive value creation for stockholders through its proven strategy and is focused on achieving its strategic plan, including commercial pipeline testing goals and positive EBITDA by the end of 2026.

Management Comments

• 'Our proven strategy is designed to drive value creation for stockholders.'
• 'Fiscal 2023 was a consequential year for our Company, as we grew revenue by 60% to $220 million.'
• 'We continued stockholder engagement, including a robust, Board-driven stockholder outreach program during the fall of 2023.'

Industry Context

In the diagnostics industry, companies are increasingly focused on personalized medicine and clinically actionable test results. Castle Biosciences' efforts to align executive compensation with company performance and stockholder interests are consistent with best practices in corporate governance.

Comparison to Industry Standards

• Peer groups for executive compensation typically include companies of similar size, revenue, and market capitalization within the same industry.
• The move to a 3-year performance period for long-term incentives aligns with common practices among publicly traded companies.
• Adopting stock ownership guidelines and a clawback policy are standard risk mitigation practices for executive compensation.
• Companies like Exact Sciences and Myriad Genetics are comparable in terms of market capitalization and focus on diagnostic testing.

Corporate Governance

Stakeholder Impact

• Stockholders: The changes to executive compensation and corporate governance are intended to align management interests with stockholder value.
• Employees: The company's performance-based compensation programs are designed to incentivize employees to achieve the company's strategic goals.
• Customers: The company's focus on personalized medicine and clinically actionable test results is intended to improve patient outcomes.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Stockholders on May 23, 2024.
• The company will continue to monitor and respond to stockholder feedback on executive compensation and corporate governance matters.

Key Dates

Keywords

executive compensation, say-on-pay, stockholder engagement, proxy statement, annual meeting, performance metrics, revenue growth, EBITDA, stock ownership guidelines, clawback policy